An Interview With MannKind CEO Michael Castagna
Castagna: Yeah, I think we've already demonstrated that we've surpassed Sanofi's sales curves. I was actually a shareholder of MannKind when they got [Afrezza] approved. And I think those trends over the next six months will really start to show people what can happen. Castagna: I think in terms of turning into prescriptions, it will take about two months to start to see a meaningful lift.